Page last updated: 2024-12-08
etilevodopa
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
etilevodopa: is the ethyl ester of levodopa; an antiparkinson drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 170345 |
| CHEMBL ID | 1823681 |
| CHEBI ID | 135971 |
| SCHEMBL ID | 584493 |
| MeSH ID | M0460318 |
Synonyms (42)
| Synonym |
|---|
| l-dopa ethyl ester |
| etilevodopa |
| tv-1203 |
| levodopa ethyl ester |
| etilevodopa (usan/inn) |
| D04097 |
| 37178-37-3 |
| CHEBI:135971 |
| ethyl (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoate |
| CHEMBL1823681 |
| 895x917gye , |
| unii-895x917gye |
| (-)-3,4-dihydroxy-l-phenylalanine, ethyl ester |
| etilevodopa [usan:inn] |
| o-ethyl-dopa |
| l-tyrosine, 3-hydroxy-, ethyl ester |
| AKOS015933284 |
| AKOS010395756 |
| 3,4-dihydroxy-l-phenylalanine ethyl ester |
| etilevodopa [who-dd] |
| 3-hydroxy-l-tyrosine ethyl ester |
| etilevodopa [inn] |
| 3-hydroxy-tyrosine ethyl ester |
| etilevodopa [usan] |
| SCHEMBL584493 |
| CCG-221888 |
| 2(s)-amino-3-(3,4-dihydroxyphenyl)propionic acid ethyl ester |
| mfcd00871210 |
| F52325 |
| l-dopa ethyl ester, >=98% (hplc) |
| NULMGOSOSZBEQL-QMMMGPOBSA-N |
| (s)-ethyl 2-amino-3-(3,4-dihydroxyphenyl)propanoate |
| DTXSID10905092 |
| Q5404593 |
| (s)-ethyl 2-amino-3-(3,4-dihydroxyphenyl)propanoate (h-l-tyr(3-oh)-oet) |
| CS-0063515 |
| HY-116016 |
| DB06535 |
| ethyl (s)-2-amino-3-(3,4-dihydroxyphenyl)propanoate |
| NCGC00408874-03 |
| l-dopa ethyl ester;levodopa ethyl ester |
| EN300-150307 |
Research Excerpts
Overview
Etilevodopa is an ethyl-ester prodrug of levodopa. It has greater gastric solubility and passes quickly into the small intestine. It is rapidly hydrolyzed to levodOPA, and has a shortened time to maximum concentration.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Etilevodopa is a unique, highly soluble prodrug of levodopa." | ( Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Djaldetti, R; Giladi, N; Hassin-Baer, S; Melamed, E; Shabtai, H, ) | 1.18 |
| "Etilevodopa is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration." | ( A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Blindauer, K; Eyal, E; Fahn, S; Goetz, C; Goren, S; Kieburtz, K; Levy, R; Nutt, J; Oakes, D; Pagano, M; Salzman, P; Sayag, N; Schwid, S; Scolnik, M; Shoulson, I; Stern, M, 2006) | 1.34 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " To measure the maximal concentration (Cmax), time to Cmax (tmax), and area under the curve (AUC) of plasma levodopa, etilevodopa, and carbidopa, blood samples were drawn before drug administration and at intervals up to 240 minutes thereafter." | ( Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Djaldetti, R; Giladi, N; Hassin-Baer, S; Melamed, E; Shabtai, H, ) | 0.66 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| tyrosine derivative | An amino acid derivative resulting from reaction of tyrosine at the amino group or the carboxy group, any substitution of phenyl hydrogens, or from the replacement of any hydrogen of tyrosine by a heteroatom. The definition normally excludes peptides containing tyrosine residues. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID615024 | Half life in human plasma | 2009 | Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10 | QSAR models for predicting enzymatic hydrolysis of new chemical entities in 'soft-drug' design. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.13) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||